QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

URGN

QT80UroGen Pharma Ltd.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
33.57
+0.76+2.32%
OverviewShort InterestFilings
URGNQT80UroGen Pharma Ltd.·NASDAQ
OverviewShort InterestFilings
33.57+2.32%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.75
Insider Own5.82%
Shs Outstand48.72M
Perf Week13.80%
Market Cap1.60BForward P/E27.32EPS next Y1.23Insider Trans0.11%Shs Float-Perf Month18.79%
Enterprise Value1.68BPEG-EPS next Q-0.30Inst Own-Short Float-Perf Quarter80.58%
Income-129323424.00P/S11.38EPS this Y67.09%Inst Trans-Short Ratio-Perf Half Y43.03%
Sales140.49MP/B-EPS next Y235.77%ROA-52.51%Short Interest-Perf YTD43.34%
Book/sh-2.55P/C-EPS next 5Y-ROE121.52%52W High33.79 -0.65%Perf Year153.55%
Cash/sh2.91P/FCF-EPS past 3/5Y-ROIC-50.85%52W Low12.73 163.71%Perf 3Y-
Dividend Est.-EV/EBITDA-14.55Sales past 3/5Y19.79% 55.76%Gross Margin89.85%Volatility3.81% 4.00%Perf 5Y-
Dividend TTM-EV/Sales11.99EPS Y/Y TTM7.09%Oper. Margin-77.02%ATR (14)1.68Perf 10Y-
Dividend Ex-Date-Quick Ratio4.28Sales Y/Y TTM55.56%Profit Margin-94.83%RSI (14)73.01Recom2.27
Dividend Gr. 3/5Y-Current Ratio4.69EPS Q/Q48.91%SMA2015.59%Beta1.22Target Price42.50
Payout0.00%Debt/Eq-1.59Sales Q/Q155.00%SMA5025.32%Rel Volume1.01Prev Close32.81
Employees234LT Debt/Eq-1.22EarningsAug 06SMA20051.90%Avg Volume830.51KPrice33.57
IPO DateMay 04, 2017Option/ShortYes / YesEPS/Sales Surpr.16.07% 13.33%Net Debt/EBITDA-0.74Volume834,760Change2.32%
Analyst Ratings
DateActionAnalystRatingTarget
May-11-26ReiteratedH.C. WainwrightBuy$40 → $45
Apr-09-26InitiatedJefferiesBuy$40
Jun-16-25UpgradeHC Wainwright & Co.Neutral → Buy
Jun-13-25ReiteratedGoldman SachsNeutral$3.00 → $16
Jun-13-25ReiteratedOppenheimerOutperform$40 → $31
May-22-25DowngradeHC Wainwright & Co.Buy → Neutral
Jun-14-24ReiteratedEvercore ISI$46
Jun-14-24ReiteratedH.C. WainwrightBuy$54 → $60
Jun-14-24ReiteratedGoldman SachsNeutral$22
Jun-14-24ReiteratedOppenheimerOutperform$32 → $40
Latest News
Jun-10-26
Jun-10-2602:42PM
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue14011090
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A14129
Gross Profit1279782
Selling, General and Administrative Excl. Other1711550
Research and Development636757
Other Operating Expense10121
Operating Income-107-125-97
Interest Expense393413
Unusual Expense
———
Non-Operating Income (Expense)1013-1
Net Income Before Taxes-138-153-124
Income Taxes-503
Consolidated Net Income-133-153-127
Net Income From Continuing Operations-133-153-127
Net Income-133-153-127
EPS (Recurring)-2.75-3.19-2.96
EPS (Basic, Before Extraordinaries)-2.75-3.19-2.96
EPS (Diluted)-2.75-3.19-2.96
EBITDA-116-136-95
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio11.9910.22—
Gross Margin90.7188.1891.11
Operating Margin-76.43-113.64-107.78
Net Margin-95.00-139.09-141.11
Shares Outstanding504843
Market Capitalization1,6791,124—
Operating Lease Expense
———
Insider Trading Volume
$36.04$31.80$27.55$23.31$19.07● Close Price0.00K75.00K150.00K225.00K300.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schoenberg MarkChief Medical OfficerJun 08 '26Sale27.305,222142,561139,763Jun 09 12:00 AM
Schoenberg MarkChief Medical OfficerJun 08 '26Option Exercise0.0020,0000144,985Jun 09 12:00 AM
Robinson James A. Jr.DirectorMay 26 '26Option Exercise0.004,00006,000May 27 12:00 AM
Schoenberg MarkChief Medical OfficerMay 08 '26Sale30.0010,000300,000134,985May 11 12:00 AM
Robinson James A. Jr.DirectorFeb 26 '25Option Exercise0.004,00004,000Feb 27 12:00 AM
Smith Jason DrewGeneral CounselFeb 03 '26Sale19.697,479147,26251,326Feb 11 12:00 AM
Smith Jason DrewGeneral CounselJan 31 '26Option Exercise0.0031,000058,805Feb 11 12:00 AM
Schoenberg MarkChief Medical OfficerFeb 03 '26Sale19.697,373145,174144,985Feb 04 12:00 AM
Schoenberg MarkChief Medical OfficerJan 31 '26Option Exercise0.0026,6660152,358Feb 03 12:00 AM
Holden StuartDirectorNov 26 '25Option Exercise0.004,00006,000Dec 01 12:00 AM
BUTITTA CYNTHIA MDirectorNov 26 '25Option Exercise0.004,00006,000Dec 01 12:00 AM
Robinson James A. Jr.DirectorNov 26 '25Option Exercise0.004,00006,000Dec 01 12:00 AM
WEN LEANADirectorNov 26 '25Option Exercise0.004,00006,000Dec 01 12:00 AM
Wildman Daniel GeorgeDirectorNov 26 '25Option Exercise0.004,00006,000Dec 01 12:00 AM
Schoenberg MarkChief Medical OfficerNov 19 '25Sale25.0010,000250,000139,025Nov 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR